The regulation of normal melanocyte proliferation

被引:145
作者
Halaban, R [1 ]
机构
[1] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA
来源
PIGMENT CELL RESEARCH | 2000年 / 13卷 / 01期
关键词
receptor kinase; Ras; MAPK; pRB; p107; p130; E2F;
D O I
10.1034/j.1600-0749.2000.130103.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In vitro, normal human melanocytes require synergistic mitogens, in addition to the common growth factors present in serum, in order to proliferate. The peptide growth factors that confer stimulation are fibroblast growth factors (such as bFGF/FGF2), hepatocyte growth factor/scatter factor (HGF/ SF), mast/stem fell factor (M/SCF), endothelins (such as ET-1) and melanotropin (MSH), The proper function of these factors and their cognate receptors is Likely to be important in vivo, as all five ligands are produced in the skin, and disruption of their normal function, by elimination due to deletions or mutations, or overproduction due to ectopic expression, disrupts the normal distribution of melanocytes. The synergistic growth factors activate intracellular signal transduction cascades and maintain the intermediate effecters at optimal levels and duration required for nuclear translocation and modification of transcription factors. The consequent induction of immediate-early response genes, such as cyclins, and subsequent activation of cyclin-dependent kinases (CDK4, CDK6 and CDK2) inactivates the retinoblastoma family of proteins (pRb, p107 and p130, together termed pocket proteins), and releases their suppressive association with E2F transcription factors. Molecular events that disrupt this tight control of pocket proteins and cause their inactivation, increase E2F transcriptional activity and confer autonomous growth on melanocytes.
引用
收藏
页码:4 / 14
页数:11
相关论文
共 160 条
[1]   MITOGENIC AND MELANOGENIC STIMULATION OF NORMAL HUMAN MELANOCYTES BY MELANOTROPIC PEPTIDES [J].
ABDELMALEK, Z ;
SWOPE, VB ;
SUZUKI, I ;
AKCALI, C ;
HARRIGER, MD ;
BOYCE, ST ;
URABE, K ;
HEARING, VJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1789-1793
[2]  
Adams PD, 1996, CURR TOP MICROBIOL, V208, P79
[3]   TRANSCRIPTIONAL CONTROL BY E2F [J].
ADAMS, PD ;
KAELIN, WG .
SEMINARS IN CANCER BIOLOGY, 1995, 6 (02) :99-108
[4]  
Adams PD, 1999, MOL CELL BIOL, V19, P1068
[5]   Heterozygous endothelin receptor B (EDNRB) mutations in isolated Hirschsprung disease [J].
Amiel, J ;
Attie, T ;
Jan, D ;
Pelet, A ;
Edery, P ;
Bidaud, C ;
Lacombe, D ;
Tam, P ;
Simeoni, J ;
Flori, E ;
NihoulFekete, C ;
Munnich, A ;
Lyonnet, S .
HUMAN MOLECULAR GENETICS, 1996, 5 (03) :355-357
[6]   MUTATION OF THE ENDOTHELIN-RECEPTOR-B GENE IN WAARDENBURG-HIRSCHSPRUNG-DISEASE [J].
ATTIE, T ;
TILL, M ;
PELET, A ;
AMIEL, J ;
EDERY, P ;
BOUTRAND, L ;
MUNNICH, A ;
LYONNET, S .
HUMAN MOLECULAR GENETICS, 1995, 4 (12) :2407-2409
[7]  
Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO
[8]  
2-#
[9]   The retinoblastoma protein pathway and the restriction point [J].
Bartek, J ;
Bartkova, J ;
Lukas, J .
CURRENT OPINION IN CELL BIOLOGY, 1996, 8 (06) :805-814
[10]  
Bartkova J, 1996, CANCER RES, V56, P5475